Wedbush Reiterates “Outperform” Rating for Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Wedbush reiterated their outperform rating on shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA) in a research note published on Monday morning,RTT News reports. The firm currently has a $34.00 target price on the stock. Wedbush also issued estimates for Kiniksa Pharmaceuticals’ Q1 2025 earnings at $0.10 EPS, Q2 2025 earnings at $0.11 EPS, Q3 2025 earnings at $0.15 EPS, FY2025 earnings at $0.56 EPS, FY2026 earnings at $1.07 EPS and FY2027 earnings at $1.44 EPS.

Several other equities analysts have also weighed in on KNSA. Evercore ISI raised their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Wednesday, October 30th. JPMorgan Chase & Co. increased their price target on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $36.60.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock opened at $18.82 on Monday. Kiniksa Pharmaceuticals has a 12 month low of $16.56 and a 12 month high of $28.15. The company’s fifty day simple moving average is $20.94 and its 200-day simple moving average is $23.27.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last issued its earnings results on Tuesday, October 29th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. The firm had revenue of $112.21 million during the quarter, compared to analysts’ expectations of $111.51 million. During the same quarter last year, the firm earned ($0.20) EPS. The business’s revenue for the quarter was up 67.4% compared to the same quarter last year. On average, analysts forecast that Kiniksa Pharmaceuticals will post -0.55 EPS for the current year.

Insider Activity

In other news, CFO Mark Ragosa sold 8,969 shares of Kiniksa Pharmaceuticals stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total value of $192,385.05. Following the transaction, the chief financial officer now directly owns 22,958 shares in the company, valued at approximately $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction dated Monday, January 13th. The stock was sold at an average price of $18.24, for a total value of $255,360.00. Following the transaction, the chief operating officer now directly owns 88,975 shares of the company’s stock, valued at $1,622,904. This represents a 13.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 24,092 shares of company stock valued at $471,609 over the last 90 days. 54.57% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Essex Investment Management Co. LLC increased its position in Kiniksa Pharmaceuticals by 0.4% during the third quarter. Essex Investment Management Co. LLC now owns 200,516 shares of the company’s stock worth $5,011,000 after acquiring an additional 717 shares during the period. Franklin Resources Inc. grew its position in Kiniksa Pharmaceuticals by 1.7% in the 3rd quarter. Franklin Resources Inc. now owns 67,533 shares of the company’s stock worth $1,798,000 after purchasing an additional 1,100 shares during the last quarter. CWM LLC increased its holdings in shares of Kiniksa Pharmaceuticals by 443.0% during the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after purchasing an additional 1,998 shares during the period. Quarry LP acquired a new position in shares of Kiniksa Pharmaceuticals during the third quarter valued at about $50,000. Finally, Bank of New York Mellon Corp raised its position in shares of Kiniksa Pharmaceuticals by 2.3% during the second quarter. Bank of New York Mellon Corp now owns 115,143 shares of the company’s stock valued at $2,150,000 after buying an additional 2,563 shares during the last quarter. 53.95% of the stock is owned by institutional investors.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.